National and Kapodistrian University of Athens
Μελέτη του νέου αποπτωτικού γονιδίου BCL2L12
Abstract
dc:descriptionThe aim of this thesis is expression analysis and clinical evaluation of the novel apoptosis-related gene BCL2L12 in human leukemia cells and patients with acute myeloid leukemia. Scorilas et al., recently, discovered and cloned a new member of the BCL2 gene family, BCL2L12, that it was found to be implicated in many types of solid tumors having promising differential diagnostic and prognostic value. During the first part of the thesis, HL60 human leukemia cells stimulated with the common chemotherapeutic agents topotecan, methotrexate, etoposide, vincristine, taxol and As2O3. These antineoplastic drugs are able to cause cell death, in HL60 cels, through the induction of apoptosis. The kinetics of the induction of apoptosis and cell toxicity were investigated by DNA laddering and MTT method, respectively. Total RNA was extracted and cDNA was prepared by reverse transcription. The studied genes were amplified by PCR using gene specific primers. Expression of the genes was evaluated based on ethidium bromide visualization of the PCR product on agarose gels. Β-ACTIN and GAPDH were used as housekeeping genes. For the first time, significant modulations in the BCL2L12 mRNA expression, after the studied drug stimulation in HL60 cells, were observed. In the cases of topotecan and etoposide-induced apoptosis, the results showed a downregulation of BCL2L12 mRNA in the late stages of apoptosis. After treatment with either vincristine or taxol, we observed an increased mRNA expression of both BCL2L12 and BCL2, in the beginning of apoptosis and a gradual downregulation of the mRNA expression of these genes through the progression of apoptotic phenomenon. In the case of methotrexate-induced apoptosis, we also observed a decrease in the mRNA expression of BCL2L12, 6h after drug treatment. Finally, a gradual downregulation of BCL2L12 m RNA level was demonstrated after treatment of the HL-60 cell line with As2O3. These modulations in the expression of BCL2L12 gene, after treatment of the leukemia cells with these drugs, may be an underlying mechanism through, as yet, unknown apoptotic pathways. These observations may be due to the pro-apoptotic or anti-apoptotic effects of the gene. During the second part of the thesis, the expression of the novel apoptosis related gene, BCL2L12, in blood samples from patients with acute myeloid leukaemia and healthy controls were also, for the first time, investigated. A highly sensitive quantitative real time (QRT-PCR) methodology, using the SYBR Green I chemistry, has been used for BCL2L12 quantification in blood from the selected patients. Follow-up information was available for a statistical significant size of the leukemia patients (n=46). A computerized database containing all the information concerning each patient was available for statistical analysis. The associations between mRNA expression level of the novel gene BCL2L12 and clinical/pathological characteristics were evaluated by using chi-square test (χ2) or the Fisher’s exact test, where appropriate. According to our clinical study, leukemia patients with positive BCL2L12 expression status (according to calculated optimal cut-off) were 3 times more likely to relapse or die than patients with negative BCL2L12 expression. In addition, statistical significant relationships (p<0.05) were found between BCL2L12 expression and CD117, Splenomegaly and Chemotherapy Response. Therefore, our data support the hypothesis that BCL2L12 may be characterized as a new prognostic marker in acute myeloid leukemia.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Floros, Konstantinos
- Φλώρος, Κωνσταντίνος
Subjects
dc:subject × 19Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27844